BridgeBio Pharma (NASDAQ:BBIO) posted its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.04, Yahoo Finance reports. The business had revenue of $26.74 million for the quarter.
Shares of BBIO traded up $2.64 during trading hours on Friday, hitting $27.06. The stock had a trading volume of 290,200 shares, compared to its average volume of 279,343. The stock has a fifty day simple moving average of $20.94. BridgeBio Pharma has a 12-month low of $17.61 and a 12-month high of $32.94.
Several equities research analysts have recently issued reports on the company. Jefferies Financial Group assumed coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set a “buy” rating and a $38.00 price objective on the stock. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a report on Friday, October 18th. Leerink Swann assumed coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set an “outperform” rating and a $34.00 price objective on the stock. Raymond James assumed coverage on BridgeBio Pharma in a report on Friday, July 26th. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Goldman Sachs Group assumed coverage on BridgeBio Pharma in a report on Monday, July 22nd. They set a “buy” rating and a $42.00 price objective on the stock. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $40.13.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.
Featured Story: What is range trading?
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.